|1.||Gaestel, Matthias: 5 articles (01/2015 - 11/2007)|
|2.||Davis, Terence: 2 articles (01/2015 - 01/2013)|
|3.||Bagley, Mark C: 2 articles (01/2015 - 01/2013)|
|4.||Kipling, David: 2 articles (01/2015 - 01/2013)|
|5.||Lander, Cynthia: 2 articles (12/2014 - 07/2013)|
|6.||Birner, Peter: 2 articles (12/2014 - 04/2012)|
|7.||Schoppmann, Sebastian F: 2 articles (12/2014 - 04/2012)|
|8.||Lu, Jiachun: 2 articles (01/2014 - 08/2012)|
|9.||Zhou, Yifeng: 2 articles (01/2014 - 08/2012)|
|10.||Li, Yinyan: 2 articles (01/2014 - 08/2012)|
06/01/2003 - "We, therefore, compared the infarct:risk volume ratio (I:R%) after 30-min global ischemia in Langendorff-perfused hearts from outbred C57BL/6 mice with that in wild-type mice derived from heterozygote x heterozygote crosses of two different in-house C57BL/6 mouse lines with targeted disruption of an MKK3 or MAPKAPK2 allele. "
02/04/2000 - "MAPKAPK2 activity was not altered in control hearts after 20 minutes of global ischemia. "
02/04/2000 - "Ventricular biopsies before treatment and after 20 minutes of ischemia were homogenized, and the activities of MAPKAPK2 and JNK were evaluated. "
01/01/1999 - "CK2 and hsp27 kinase activities declined during global ischemia in control hearts, whereas PC with 5 min ischemia and 10 min reperfusion increased their activities during global ischemia. "
01/01/2005 - "Ischemia/reperfusion potentiates activation of p38 MAP kinase (p38MAPK) leading to the activation of its downstream target MAPKAP kinase 2 (MK2). "
|2.||Werner Syndrome (Werner's Syndrome)
01/01/2013 - "The effect of small-molecule inhibition of MAPKAPK2 on cell ageing phenotypes of fibroblasts from human Werner syndrome."
01/01/2015 - "Microwave-assisted Suzuki-Miyaura cross-coupling reactions have been employed towards the synthesis of three different MAPKAPK2 (MK2) inhibitors to study accelerated aging in Werner syndrome (WS) cells, including the cross-coupling of a 2-chloroquinoline with a 3-pyridinylboronic acid, the coupling of an aryl bromide with an indolylboronic acid and the reaction of a 3-amino-4-bromopyrazole with 4-carbamoylphenylboronic acid. "
|3.||Lung Neoplasms (Lung Cancer)
08/10/2012 - "Our study establishes a robust association between the functional g.CNV-30450 in MAPKAPK2 and risk as well as prognosis of lung cancer, and it presents this functional copy-number variation as a potential biomarker for susceptibility to and prognosis for lung cancer."
08/10/2012 - "A functional copy-number variation in MAPKAPK2 predicts risk and prognosis of lung cancer."
08/10/2012 - "To assess whether the copy-number variation g.CNV-30450 located in the MAPKAPK2 promoter has any effect on lung cancer risk or prognosis, we investigated the association between g.CNV-30450 and cancer risk in three independent case-control studies of 2,332 individuals with lung cancer and 2,457 controls and the effects of g.CNV-30450 on cancer prognosis in 1,137 individuals with lung cancer with survival data in southern and eastern Chinese populations. "
04/01/2011 - "Increased activation of p38MAPK, MAPKAPK2, and Hsp27 was observed in lung cancer stem cells compared with control A549 cells both before and after exposure to superoxide and chemotoxic agents. "
|4.||Prostatic Neoplasms (Prostate Cancer)
05/18/2006 - "This study demonstrates that both MAPKAPK2 and HSP27 are necessary for TGFbeta-mediated increases in MMP-2 and cell invasion in human prostate cancer."
05/18/2006 - "MAPKAPK2 and HSP27 are downstream effectors of p38 MAP kinase-mediated matrix metalloproteinase type 2 activation and cell invasion in human prostate cancer."
|2.||Heat-Shock Proteins (Heat-Shock Protein)
|4.||Protein-Tyrosine Kinases (Tyrosine Kinase)
|5.||Transforming Growth Factor beta (TGF-beta)
|8.||p38 Mitogen-Activated Protein Kinases
|9.||Protein Kinases (Protein Kinase)
|10.||MAP-kinase-activated kinase 3